Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Shares Slide 5 Percent on USDA Report of False-Positive Mad Cow Test Results

NEW YORK, Nov. 24 (GenomeWeb News) - Shares in Bio-Rad Laboratories fell nearly 5 percent on Wednesday afternoon, a day after the US Department of Agriculture said the firm's rapid-screening test kit for bovine spongiform encephalopathy had generated a false-positive in screening cattle for the disease.


Because the ELISA-based test, which uses antibodies to rapidly detect the prions that cause the brain-wasting disease, was known to provide some false-positives, the USDA had called the initial test result last week "inconclusive."


According to a statement issued by the USDA late yesterday, test results were reactive in both the first and second screens of the animal suspected of having the disease. The department's National Veterinary Services Laboratories then ran the standard immunohistochemistry test a second time on the sample, and, for the second time on the IHC test, the result was negative.


"Negative results from both IHC tests makes us confident that the animal in question is indeed negative for BSE," the USDA said in a statement.


The department noted that this is the third time the Bio-Rad rapid test had generated a false positive result.


In a statement issued after the USDA's announcement, Bio-Rad said, "The test is designed to be extremely sensitive so that it will detect any sample with the potential of being positive."


Shares in the Hercules, Calif.-based firm dropped $2.78, or 4.8 percent, in mid-afternoon trade on the American Stock Exchange.


The pull back comes after a recent run-up in Bio-Rad's share price, which started the day after the USDA reported that results from the two rapid screening tests for BSE were inconclusive. The news led to concern that, almost a year to the day, the nation's beef supply may have been contaminated from a cow with the disease.


As reported in yesterday's issue of BioCommerce Week, a GenomeWeb News publication, Bio-Rad closed Monday at $56.55, up nearly 6 percent since the markets opened on Thursday.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.